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Abstract
Intramuscular expression of functional proteins is a promising strategy for therapeutic purposes.
Previously, we developed an intramuscular gene delivery method by combining Pluronic L64 and
optimized electropulse, which is among the most efficient methods to date. However, plasmid
DNAs (pDNAs) in this method were not compressed, making them unstable and inefficient in vivo.
We considered that a proper compression of pDNAs by an appropriate material should facilitate
gene expression in this L64-electropulse system. Here, we reported our finding of such a material,
Epigallocatechin gallate (EGCG), a natural compound in green teas, which could compress and pro-
tect pDNAs and significantly increase intramuscular gene expression in the L64-electropulse sys-
tem. Meanwhile, we found that polyethylenimine (PEI) could also slightly improve exogenous gene
expression in the optimal procedure. By analysing the characteristic differences between EGCG
and PEI, we concluded that negatively charged materials with strong affinity to nucleic acids and/or
other properties suitable for gene delivery, such as EGCG, are better alternatives than cationic
materials (like PEI) for muscle-based gene delivery. The results revealed that a critical principle for
material/pDNA complex benefitting intramuscular gene delivery/expression is to keep the complex
negatively charged. This proof-of-concept study displays the breakthrough in compressing pDNAs
and provides a principle and strategy to develop more efficient intramuscular gene delivery sys-
tems for therapeutic applications.
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Introduction
It is an attractive strategy to produce therapeutic molecules using
myocytes in skeletal muscles through intramuscular delivery of func-
tional genes [1]. In this kind of gene therapy trials, naked plasmids
have distinct advantages over viral vectors, such as biosafety,
simplicity and cost efficiency [2]. Although in the pioneer study, ‘na-
ked’ plasmid DNAs (pDNAs) were introduced into myocytes to suc-
cessfully express reporter genes, direct administration of pDNAs
showed unsatisfying results in therapeutic trials because of its low
gene delivery efficiency [3]. Thereafter, efforts have been dominantly
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focusing on increasing delivery efficiency of pDNAs. Plenty of stud-
ies have revealed that it is an appealing way to transfer plasmids by
using physical assistance, such as ultrasound, microbubbles and the
most widely used electroporation [2, 4–9]. Besides, it is also worth
noting that some chemical reagents such as poly(N-vinyl-pyrroli-
done), poly(vinyl alcohol) and especially Pluronics are capable of
promoting the efficiency of intramuscular gene delivery [10–15].
However, each approach has its own disadvantages and limitations.
For example, the commonly used physical methods like electropora-
tion and ultrasound still show potential safety risks to the body as
well as histological damage or/and functional deterioration of local
tissue [16, 17]. More and more researchers are developing combined
strategies to enhance the gene expression level and reduce tissue
toxicity.
In a previous study, we created an efficient and safe intramuscu-
lar gene delivery method by combining Pluronic L64 and low-
voltage electropulse [18]. In this procedure, Pluronic L64 could in-
teract with the cell membrane, disturb its integrity and increase its
permeability, which consequently facilitated the migration of
pDNAs driven by the low-voltage electropulse across the permeabi-
lized membrane. Moreover, L64 has been proven to have the ability
to accelerate the escape of pDNAs from endosomes and lysosomes
[19]. The L64-electropulse method is among the most efficient intra-
muscular gene transfer procedures to date. However, pDNAs were
still ‘naked’ in this procedure because they did not interact with L64
molecules.
Naked nucleic acids can be degraded by nucleases easily and rap-
idly in both the extracellular matrix (ECM) and intracellular envi-
ronments [20]. Meanwhile, naked DNA would be unsuitable for
efficient transmembrane migration in comparison with its com-
pressed nanoscale counterparts [21]. Therefore, we expect that the
transgene expression level of the L64-electropulse method could be
significantly improved if the pDNAs were properly compressed and
protected by an appropriate material. To compress pDNAs, the
dominant approach is the application of non-viral cationic materials
as vectors or carriers [22]. These cationic materials intact with an-
ionic nucleic acids via electrostatic interactions, and the final mate-
rial/pDNA complexes are usually cationic nanoparticles with
optimized size and shape for effective in vitro gene transfection.
However, cationic particles have been widely confirmed to be inef-
fective for intramuscular gene delivery and expression [23–25]. This
may be due to the completely different extracellular environment of
cultured cells compared with that of skeletal myocytes [26].
Negatively charged ECM components could bind positively charged
material/pDNA complexes after local administration, which might
disturb their mobility in tissue or interaction with target cells, result-
ing in a poor in vivo gene delivery/expression result [27–29]. Thus,
to prevent non-specific interactions with ECM components, we
think that the material/pDNA complex with negative charge might
be an effective approach for the L64-electropulse-mediated intra-
muscular gene delivery system. It is hypothesized that the lower ma-
terial/pDNA ratio, compared with that for optimized cell
transfection, might result in negatively charged nanoparticle, thus
facilitating in situ gene transfer to myocytes. However, it is still un-
certain if the reduced material/pDNA ratio may bring about effec-
tive compression of pDNAs, and more importantly, offer efficient
expression of the transgene.
Herein, we considered that the development of another type of
gene vector with negative charge or even neutral could be an alterna-
tive strategy for in situ gene transfer into skeletal muscles.
Epigallocatechin gallate (EGCG), a principal and the most widely
studied component of green tea catechins, seems to be an ideal can-
didate because of its properties [30]. First, EGCG with phenolic hy-
droxyl groups has shown strong affinity to DNA via cooperative
hydrogen bonds and hydrophobic interactions rather than electro-
static interactions [31–33]. Second, EGCG can penetrate or be
absorbed into the lipid bilayer of cell membranes [34–36], thus facil-
itating the translocation of EGCG/pDNA complexes across the
membranes. Finally, EGCG can inhibit the activity of some nucle-
ases by blocking their active sites [37–39], which may further
strengthen the protective effect on DNA against enzymatic
degradation.
In this proof-of-concept study, we investigated if the EGCG-
compressed pDNAs can significantly improve intramuscular gene
expression based on the L64-electropulse method. As the typical cat-
ionic vector, polyethylenimine (PEI) was investigated as a control to
explore the influence of the zeta potentials of PEI/pDNA complexes
with different N/P ratios on the transgene expression level and tissue
toxicity in skeletal muscles. We expect to set up an efficient intra-
muscular gene delivery/expression system, and more importantly, to
find out critical factors determining the proper compression and
protection of pDNAs in such muscle-based transgene systems.
Materials and methods
Materials
Pluronic L64 and branched polyethylenimine (bPEI, Mw = 25 kDa)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tea
polyphenol powder (EGCG wt% 80%) was obtained from Wuxi
Taiyo Green Power Co. Ltd. (Jiangsu, China). DNase I and DNase I
reaction buffer were obtained from Invitrogen (Carlsbad, CA, USA).
HBG buffer (HEPES 20 mM, pH 7.4, 5% (w/v) glucose) and other
buffers were prepared in MilliQ ultrapure water and filtered
(0.22lm) prior to use. All other chemicals were purchased from
Sigma-Aldrich and used without further purification. All chemicals
and reagents were of analytical grade.
The plasmids encoding b-D-galactosidase (pCMV-LacZ), lucifer-
ase (pCMV-Luc), far-red fluorescent protein (pCMV-E2) and
growth-hormone-releasing hormone (pCMV-GHRH) were previ-
ously constructed in our laboratory [18, 23, 25]. The plasmids were
amplified in E. coli DH5a and extracted using the Endo-Free
Plasmid Kit (Invitrogen, Carlsbad, CA, USA).
Preparation and characterization of PEI/pDNA
polyplexes and EGCG/pDNA mixtures
The N/P ratio of PEI to pDNA is defined as the molar ratio of nitro-
gen in PEI to phosphates in pDNA. PEI/pDNA polyplexes or
EGCG/pDNA mixtures were prepared in HBG buffer by adding var-
iable amounts of PEI or EGCG solutions into equal volume of solu-
tions containing fixed amount of pDNAs. Each resultant
formulation was incubated for 30 min at room temperature before
use.
The nanoparticle size (diameter, nm), polydispersity index (PDI)
and zeta potential (f) were measured on a Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, UK) dynamic light scattering
(DLS) instrument. The samples were diluted to 1 ml with MilliQ wa-
ter to a final DNA concentration of 3mg ml1. All measurements
were performed in triplicate at 25C. The morphology and size of
particles were examined by atomic force microscope (AFM, MFP-
3D-BIO, USA). Briefly, samples were prepared at a final DNA con-
centration of 20mg ml1 and then spread out on freshly cleaved
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mica sheets. After an overnight adsorption, samples were detected
using AFM.
DNase I protection assay
PEI/pDNA complexes or EGCG/pDNA mixtures containing 400 ng
pDNAs (pCMV-Luc) were incubated with 0.5 U DNase I (1 U ll1,
Fermentas) at 37C for 10 min in 10ml solution. Samples were then
treated with 5ml of 25 mM EDTA and subsequently bathed at 65C
for 10 min to inactivate the enzyme. Six microlitres of heparin or
urea (10 mg ml1) were added to PEI/pDNAs or EGCG/pDNAs, re-
spectively, and incubated for another 2 h at 37C to release the
pDNAs from complexes. Samples were then assessed by electropho-
resis on a 1% (w/v) agarose gel for 45 min at 80 V. To investigate
the inhibition of nuclease activity of EGCG, DNase I was pre-
treated with EGCG for 10 min, and then pDNAs were added and in-
cubated for 10 or 30 min, followed by the above steps including in-
activation of the nuclease, release of the pDNA and running the gel
electrophoresis to compare the intensity of DNA bands.
Intramuscular transgene administration
All experiments with live animals were performed in compliance
with the relevant laws and institutional guidelines of Sichuan
University, which were approved by the ethics committee of Sichuan
University. Four- or six-week-old male BALB/c mice were used to
evaluate in vivo expression of GHRH or reporter genes, respectively.
Ten micrograms of reporter plasmids (pCMV-LacZ, pCMV-Luc
and pCMV-E2) or 25mg of pCMV-GHRH in 40ml solution were
used for each intramuscular injection. PEI/pDNAs or EGCG/
pDNAs were mixed with 0.4% (w/v) of Pluronic L64 diluted in sa-
line to get the final concentration of 0.1% L64, kept for 5 min at
room temperature and injected into each side of the tibialis anterior
(TA) muscle using a 29-gauge BD ultra-fine insulin syringe (BD,
Franklin Lakes, NJ, USA) for 2–5 s. The transcutaneous electro-
transfer was subsequently administrated using previous protocol
[18]. The different systems were constructed and named as L/E, L/E/
P and L/E/G respectively. Herein, L refers to 0.1% (w/v) Pluronic
L64, E = electrotransfer, P =PEI and G =EGCG.
In vivo assays of reporter and functional genes
expression
Experimental mice were sacrificed and muscle samples were isolated
at the indicated days after injection. For the in situ b-galactosidase
activity assay, tissues were fixed in the commercial fixative for at
least 20 min on ice. After three times of rinsing with PBS, fixed sam-
ples were stained using b-Galactosidase Staining Kit (Beyotime,
Shanghai, China) for 6 h and then photographed with a digital cam-
era. Luciferase activity was analysed using the Luciferase Reporter
Assay Kit (Promega, Madison, WI) according to the manufacturer’s
protocol. Briefly, each sample was homogenized in 1 ml ice-cold re-
porter lysis buffer and then frozen at 80C overnight. The frozen
tissues were thawed and centrifuged at 12 000 g for 3 min at 4C.
Twenty microlitre supernatant and 100ml luciferase substrate were
mixed in a 96-well plate and the luciferase activity was detected by
measuring the light emission for 10 s in a spectral scanning multi-
mode reader (Varioskan Flash; Thermo Fisher). BCA Protein Assay
Kit (Pierce, Rockford, IL, USA) was used for measuring the protein
concentration. The transgene efficiency was presented as relative
light units per milligram of total protein (RLU/mg protein). To eval-
uate the expression of GHRH, the body weight of the mice was
recorded and the concentration of GHRH in serum was measured
using the GHRH ELISA kit (Yuduo Co. Ltd., China).
The far-red fluorescent protein expression assay
Expression of E2-Crimson far-red fluorescent protein in situ was
detected by In-Vivo Imaging System (CRI Maestro, Boston, USA) at
days 7, 14 and 21 post-intramuscular injection. The legs of mice
were thoroughly depilated and mice were anaesthetized with 5%
(w/v) chloral hydrate liquid before imaging. The scanning wave-
lengths were ranged from 600 to 700 nm.
Histological section preparation and analysis
TA muscles were separated and fixed in 4% fresh neutral parafor-
maldehyde solution for 48 h, and then orderly dehydrated with gra-
dient concentrations of ethanol and pure xylene. Well-dehydrated
samples were embedded in paraffin, sliced in both cross-sections and
longitudinal sections with 10mm thickness by a rotary slicer. The
sections of specimens were photographed by a microscope (Leica
DMI 4000B; Wetzlar, Germany) after staining with haematoxylin
and eosin.
Statistical analysis
All data were reported as mean 6 standard deviation (SD) of six in-
dependent samples. Statistical data analysis was performed by
Student’s t-tests assuming a two-tailed distribution and the variance
(ANOVA) was analysed to evaluate multiple comparisons using
graphpad prism 5.0. Differences were considered statistically signifi-
cant at P values < 0.05.
Results
Zeta potential, size and morphology of PEI/pDNA and
EGCG/pDNA complexes
For PEI/pDNA polyplexes, the diameter and surface charge of the
particles were N/P ratio dependent (Fig. 1A). The average size of the
complex increased from 300 to 1200 nm at N/P3, and decreased
to smaller than 300 nm when N/P was 10. The zeta-potential value
changed from about 15 mV to þ30 mV with increasing N/P ratios.
Therefore, the negatively charged nanoparticles with relatively small
sizes were obtained, when N/P¼0.5 and 1. When N/P>3, the aver-
age size sharply decreased and the zeta-potential turned to be
positive.
For EGCG/pDNA complexes, the average size decreased
smoothly and moderately from 330 to 200 nm while molar mass ra-
tios increased from 5 to 30 (Fig. 1B). The zeta-potential of the
EGCG/pDNA particles was negative, and varied slightly between
12.5 and 16 mV. Morphology analysis by AFM showed that
both PEI/pDNA (N/P¼0.5) and EGCG/pDNA (molar ratio = 10)
were well compressed to nanoscale with nearly spherical 3D archi-
tectures (Fig. 1C and D).
Comparison of the protective effect of PEI and EGCG on
pDNAs against DNase I degradation
An indispensable prerequisite for gene carriers is to provide protec-
tion to DNA against degradation. With a routine procedure, while
DNase I was added after formation of carrier/pDNA complexes,
pDNA bands in PEI/pDNA (Fig. 2A) and EGCG/pDNA groups
(Fig. 2B) were detectable. It indicates that pDNAs were protected in
both complexes. The differences in intensity of DNA bands between
PEI groups and EGCG groups suggest that the two materials have
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different DNA protection efficiencies. PEI was more capable of pro-
tecting pDNAs from enzymatic degradation, which might be caused
by the stronger compression effects of cationic materials on pDNAs.
Figure 2C and D was used to explain the ability of enzymatic inhibi-
tion of EGCG. In an optimized procedure, EGCG was first mixed
and pre-incubated with DNase I for 10 min and then added into
pDNA solutions. The intensity of pDNA bands in EGCG groups
was almost the same as that of untreated pDNA bands, indicating
the ability of EGCG on DNase I resistance (Fig. 2C). The intensity
of DNA bands weakened but still were seen clearly within the ex-
tended incubation time of 30 min (Fig. 2D), which implied the
DNase I resistance effect of EGCG was not instantaneous. In com-
parison, PEI did not show such DNase I resistance unless it formed
PEI/pDNA complexes (data not shown). The results revealed that
EGCG and PEI had different ways to protect pDNAs. EGCG pro-
tected pDNAs by directly inhibiting the nuclease activity of DNase I
as well as by binding DNA to form a stable and compact structure,
whereas PEI depended on its compression capability of DNA.
Efficiency and biocompatibility of L/E/P system in local
gene delivery
In the L/E/P in situ gene delivery system, when pDNAs were con-
densed by PEI, the N/P ratio of PEI nitrogens to DNA phosphates
was pivotal for the expression of reporter genes and the occurrence
of cytotoxicity. The levels of b-galactosidase (Fig. 3A) and luciferase
expression (Fig. 3B) at N/P ratio 0.5 (L/E/P-0.5) were significantly
higher than that of the L/E group. However, both genes expression
sharply decreased with N/P ratios of >0.5. Quantitatively, luciferase
expression in L/E/P-0.5 increased to 29.7-fold or 2.9-fold as com-
pared with that in the naked pDNA or L/E group, respectively.
When the N/P ratio was increased to 1, 1.5 and 3, the gene
Figure 1. Characterization of PEI/pDNA polyplexes and EGCG/pDNA compounds. Zeta potential and size measurements via DLS of (A) PEI/pDNA complexes un-
der various N/P ratios and (B) EGCG/pDNA compounds with given molar ratios. Morphology and size analysis by AFM of (C) PEI/pDNA at N/P¼ 0.5 and (D) EGCG/
pDNA at molar ratio ¼ 10
Figure 2. Protection of pDNAs from DNase I degradation by PEI or EGCG. Control a: naked pDNA. Control b: naked pDNA treated with DNase I. A and B: PEI/
pDNA and EGCG/pDNA treated with DNase I for 10min. DNase I pre-treated with EGCG for 10min, and then incubated with pDNAs for (C) 10min or (D) 30min
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expression was at least three orders of magnitude lower compared
with those in the L/E/P-0.5 or even the L/E group. At N/P¼10 and
15, the gene expression has already reduced hundreds fold as com-
pared with that in the naked pDNA group. The results demonstrate
that the L/E/P formulation can enhance intramuscular gene transfer
efficiency at a specific N/P ratio.
The potential damage on muscle tissues from different treat-
ments was evaluated to account for in vivo biocompatibility. Cross-
and longitudinal-section from the injected TA muscles were pre-
pared for the histopathological analysis 7 days after treatment. As
shown in Fig. 3C, no pathological changes were found in the L/E/P-
0.5, naked pDNA and L/E groups. It indicated that binding nucleic
acids with a small amount of PEI is safe for local transgene adminis-
tration in skeletal muscles. As the N/P ratio increased, histological
sections of muscle showed more infiltration inflammatory cells and
myocyte damage. A large area of inflammatory cell infiltration and
necrotic muscle fibres appeared once N/P ratios were >10. Taken
together, N/P ratio at 0.5 is the safe and most suitable condition for
L/E/P approach in intramuscular application.
In vivo evaluation and optimization of L/E/G system
Negative charge characteristic and the traits of EGCG on bonding
DNA and inhibiting enzyme activity inspired us to replace PEI with
Figure 3. In vivo evaluation of transgene expression in L/E/P system and the histological analysis of the injected TA muscles. n¼ 6. Time: 7days after injection.
(A) Qualitative observation of b-galactosidase expression. (B) Quantitative detection of luciferase activity. (C) Representative H/E-stained tissue sections of the
injected TA muscles. (a) Naked pDNA group; (b) L/E group; (c–h) L/E/P groups with various N/P ratios ranging from 0.5, 1, 1.5, 3, 10 and 15, respectively.
**P< 0.01 vs. pDNA. Scale bar ¼ 100 mm
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EGCG to construct an original EGCG-integrated L64-electropulse
intramuscular gene transfer system (L/E/G). As shown in Fig. 4A,
L/E/G groups with EGCG/pDNA in molar ratio from 5 to 30 pro-
vided stronger LacZ expression than those in naked pDNA and the
L/E groups. This is evident from the LacZ staining and the distribu-
tion areas on the surface of TA muscles (Fig. 4A). Besides, LacZ ex-
pression level varied in different groups with the highest level
occurring at the molar ratio 10 (L/E/G-10). Further quantitative
analysis by luciferase activity assay confirmed that RLU values in L/
E/G groups were obviously higher than that in the pDNA and L/E
groups, and the maximum also occurred in the L/E/G-10 group, with
a gradual decline thereafter (Fig. 4B). The highest luciferase expres-
sion quantitatively increased to 7.6 times as compared with that in
the L/E group, and even 122 times to pDNA administration alone.
In addition, in the groups of EGCG/pDNA (without L/E) at mo-
lar ratio of 10 (Fig. 4C, k) or even as high as 60 (Fig. 4C, m), the b-
galactosidase expression was slightly higher than that in naked
pDNA group and was comparable to that in the L/E treatment
(Fig. 4C, i or j). More importantly, b-galactosidase expression level
was significantly improved when EGCG was introduced into the
L/E method (Fig. 4C, l and n). It reveals that the combination of
EGCG with L/E method generated synergistic effects on transgene
delivery and expression, and EGCG should have significant role in
the integrated L/E/G method for improving gene expression.
It is essential to consider biocompatibility of L/E/G system for
in vivo application. Haematoxylin/eosin (H/E) staining was utilized
to visualize the general or pathological morphologies of TA muscles
treated with different formulas. The results of EGCG-containing
groups (Fig. 4D, c–h), which had no pathological changes, revealed
no visible differences with control groups (Fig. 4D, a and b).
To investigate the intensity and duration of exogenous gene ex-
pression in living animals, the expression of the far-red fluorescent
protein E2-Crimson was observed in living mice at days 7, 14 and
21 after a single administration. In each group, fluorescent signals
could be analysed for at least 3 weeks without any attenuation
(Fig. 5). In terms of expression level, the L/E/G-10 exhibited the
strongest signals among the four treatments while L/E/P-0.5 was
slightly superior to naked pDNA and L/E groups. These results were
consistent with those of luciferase and b-galactosidase expression.
Therefore, all data reveal that the L/E/G method is more effective
than L/E/P method in skeletal muscle-targeted gene delivery.
Expression of functional gene using the optimized L/E/G
method
Using skeletal muscle as a “factory” to produce therapeutic proteins
is an attractive strategy for many diseases therapy. The expression
of therapeutic genes should be high enough in targeted tissues or the
circulatory system so that the biological or therapeutic results can be
detectable or visible. Therefore, we investigated the applicable po-
tentiality of L/E/G method via examining the expression of func-
tional genes. Mouse GHRH can generate strong physiological
effects on mouse growth, which can be easily detected by measuring
the body weight of a mouse. After a single administration of 50mg
plasmid pCMV-GHRH per mouse, the body weights were recorded
at days 7, 14 and 21. Comparing to the saline group, the other three
groups showed faster growth rates to varying degrees at certain
time. Among them, the optimized L/E/G-10 group exhibited the
highest accelerated growth rate in the first 21 days after an intramus-
cular injection (Fig. 6A). At the same time, the serum concentration
of serous GHRH in the L/E/G-10 treatment was higher than the
other groups at day 7 and 14 (Fig. 6B). The results of GHRH
expression demonstrate that the L/E/G-10 method has applicable
potential on gene therapy.
Discussion
The main objective for intramuscular gene expression is to ‘produce’
designed functional molecules, such as antibodies and enzymes, for
specific purposes. For plasmid-based gene expression systems, the
expression level or the amount of expressed target molecules is the
most crucial consideration. The L64-electropulse method is one of
the most efficient intramuscular gene delivery/expression methods
to date, but the plasmids here are still ‘naked’. Unconsolidated and
chemically unmodified structure features of naked DNA confer an
inherently inadequate or ineffective cellular uptake profile and ex-
tremely low biological stability to in vivo applications.
Packaging pDNAs with gene carriers in the L/E system is identi-
fied as capable of overcoming these drawbacks, and consequently
improving intramuscular gene expression. Cationic vectors are one
of the most widely used materials to package anionic DNA for pro-
tecting nucleic acids against nuclease degradation and thus promot-
ing gene transfer into cultured cells. However, the use of cationic
vectors often has adverse side effects in intramuscular gene transfer
trials. The poor results may be due to the different extracellular
environments between in vitro cultured cells and in vivo myoblasts.
For cultured cells, the relatively simple liquid extracellular environ-
ment allows cationic vector/pDNA particles to easily migrate and
combine with cell membranes. In vivo, cationic vector/pDNA par-
ticles can be bound and trapped by the negative charge of ECM
components after local administration into skeletal muscles, result-
ing in limited mobility to target cells and gene transfection.
Negatively charged vector/pDNA particles may be a solution for
this dilemma.
To address this, first PEI was selected to compress pDNAs. A se-
ries of PEI/pDNA particles were prepared with different sizes and
surface charges (Fig. 1A). With the increase of N/P ratios from 0.5
to 3, PEI/pDNA particles enlarged rapidly and reached the peak at
N/P¼3 (1300 nm, PDI = 1.0), suggesting that precipitation hap-
pened. At the same time, the value of zeta potential gradually de-
creased and approached neutral at N/P¼3 (Fig. 1A). The enlarged
size restricted the translocation of the particles in the ECM and
across cell membranes, while the neutralized charge weakened the
interaction power between the particles and the electric field, which
was considered to be the main force to drive the particles migrating
across the permeabilized cell membranes. When the N/P ratio in-
creased to 10 or 15, the PEI/pDNA particles were positively
charged, making them to be easily trapped in the ECM and detri-
mental to the muscular tissue. In fact, the highest expression effi-
ciency (Fig. 3A and B) and minimal tissue toxicity (Fig. 3C) were
achieved at the same time at N/P ratio of 0.5 (L/E/P-0.5).
Altogether, N/P ratio = 0.5 for PEI/pDNA is an optimal parameter
for muscle-based L/E/P gene delivery system. The nanoscale, nega-
tive charge and regular morphology may cooperatively contribute to
the positive performance of PEI/pDNA complexes at N/P¼0.5.
It has been proven that the N/P ratio among 10 and 15 is opti-
mum for cell transfection when 25 kDa branched PEI is used. The
complete binding of PEI with DNA usually fulfils at N/P ratio of 3
[40]. The redundant free PEI molecules can assist PEI/pDNA par-
ticles escape from endosomes via the mechanism of proton sponge
effect. At N/P ratio of 0.5, the number of PEI molecules is insuffi-
cient to completely compress pDNAs and to timely release PEI/
pDNA complexes from endosomes via the proton sponge effect.
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However, increasing the amount of PEI may bring out adverse side
effects. Therefore, it seems that it is a paradox to use PEI in the L/E-
based method. It is speculated that other cationic materials are up
against the same situation.
In view of the dilemma of cationic materials, it is necessary to
find another kind of material for the L/E procedure. An ideal
alternative material should have the ability to effectively compress
nuclear acids to form particles with negative charge, probably
through an interaction manner other than electrostatic interactions.
Here, we found that EGCG was such an ideal alternative. First,
EGCG is biodegradable, and has a negative charge as well as a high
affinity to DNA through cooperative hydrogen bond and
Figure 4. Evaluation of intramuscular transgene expression and histological analysis in L/E/G system. n¼6. Time: 7 days after injection. Representative images of
(A) b-galactosidase expression or (B) luciferase activity assay in L/E/G treatment. (a) Naked pDNA group; (b) L/E group; (c–h) L/E/G groups with different molar ra-
tios of EGCG/pDNA at 5, 10, 15, 20, 25 and 30. **P<0.01 vs. pDNA, ***P<0.001 vs. pDNA, #P< 0.05 vs. L/E, ##P<0.01 vs. L/E, ###P<0.001 vs. L/E. (C)
Qualitative evaluation of the necessity of G or L/E in L/E/G treatment. (i) Naked pDNA group; (j) L/E group; (k) G alone (molar ratio of EGCG/pDNA ¼ 10); (l) L/E/G
(molar ratio ¼ 10); (m) G alone (molar ratio at 60); (n) L/E/G (molar ratio at 60). (D) Representative H/E-stained tissue sections of the injected TA muscles after dif-
ferent treatments as indicated in A and B. Scale bar ¼ 100 mm
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hydrophobic interactions. pDNAs were efficiently compressed by
EGCG, generating EGCG/pDNA particles ranging from 200 to
330 nm, which had suitable size distribution and nanoscale architec-
ture for gene transfer into cells (Fig. 1B and D). Meanwhile, zeta
potentials of all EGCG/pDNA particles were within 12 to
16 mV, avoiding them to being trapped in the negatively charged
ECM environment in skeletal muscles via electrostatic interactions
(Fig. 1B). Second, EGCG has the property of inhibiting nuclease ac-
tivity, providing an extra protective effect on pDNAs against DNase
I digestion. EGCG can protect pDNAs by compressing them and
inhibiting DNase I activity simultaneously (Fig. 2B–D). Third, the
structural features of EGCG allow high affinity binding to lipid
bilayers of biomembranes, which might augment cellular uptake of
particles. Fourth, the anti-inflammatory effect of EGCG is specu-
lated to reduce the local acute inflammation after injection of heter-
ogenous substances, facilitating in situ expression of exogenous
genes. Finally, as a food component, EGCG is safe enough for
in vivo application. No pathological changes including inflamma-
tory cell infiltration and muscle necrosis were found in
all the EGCG-containing treatments (Fig. 4D). These findings sug-
gest that the EGCG-integrated L/E/G method has great potential
with credible biosafety for the application of intramuscular gene
delivery.
The combination of all advantages of EGCG makes it a unique
and potent integrant in the constructed L/E/G intramuscular gene
delivery/expression method. The in vivo transgene expression by the
method was assessed using both reporter and functional genes. The
results of reporter genes expression qualitatively or quantitatively
demonstrated that the highest expression level as well as the good
biocompatibility (Fig. 4D) and duration (Fig. 5) were presented by
the L/E/G-10 administration (Fig. 4A–C). At the same time, both the
effects of GHRH on mouse growth and the serous GHRH
Figure 5. Comparison of intramuscularly expressed fluorescent protein in different optimized formulas. L/E/G: molar ratio of EGCG/pDNA ¼ 10 (L/E/G-10); L/E/P:
N/P ratio of PEI/pDNA ¼ 0.5 (L/E/P-0.5). n¼ 6
Figure 6. Intramuscular expression of the GHRH. (A) Average body weights. (B) Concentration of the GHRH in circulation. (a) saline group; (b) pDNA group; (c) L/E
group; (d) L/E/G-10. n¼6. *P< 0.05 vs. groups a and b, #P<0.05 vs. other groups






/rb/advance-article-abstract/doi/10.1093/rb/rby028/5305061 by guest on 08 February 2019
concentration were significantly improved by the L/E/G-10 adminis-
tration in the functional gene expression assay (Fig. 6). The results
displayed the promising potential of the L/E/G-10 method for thera-
peutic purpose.
Conclusion
Compressing pDNAs to proper architecture with suitable surface
charge may protect nucleic acid from nuclease degradation and pro-
mote gene delivery efficiency, thus increasing exogenous gene ex-
pression level in skeletal myocytes for applicable purpose. However,
it is still difficult to find and design such appropriate non-viral mate-
rials to compress pDNAs for intramuscular gene delivery. In this
proof-of-concept study, based on the performances of PEI/pDNA
(N/P¼0.5) and EGCG/pDNA (molar mass ratio = 10), we first re-
veal that the critical principle for material/pDNA complex benefit-
ting intramuscular gene delivery/expression is to keep the complex
negatively charged. Meanwhile, from the results we could conclude
that negatively charged or even neutralized materials with strong af-
finity to nucleic acids and/or other properties suitable for gene deliv-
ery are better choices and more promising than cationic materials in
muscle-based gene delivery systems. The principle and strategy ex-
plored in this study may be advantageous to screen and design mate-
rials to develop powerful intramuscular gene expression systems for
clinical applications. The novel L/E/G approach established here has
already showed the applicable potentials, evident from the acceler-
ated body growth and the enhanced GHRH concentration of mice.
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